Acts (ad clinical trial simulation): developing advanced informatics approaches for an alzheimer's disease clinical trial simulation system
Active Project Grant Awarded Last action
- Award ID
- R01AG084236
- Recipient
-
Mayo Clinic Jacksonville (A Nonprofit Corporation) UEI GKPBCFV1QMM3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,289,663
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 66% complete
- Place of performance
- Jacksonville, FL 32224, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease and related dementias (ad/adrd) are the most common neurodegenerative brain disease and characterized by massive loss of memory and learning. Ad/adrd affects more than 6 million americans and puts a heavy burden on caregivers in society. However, effective treatment of ad/adrd is still lacking. While randomized clinical trials (RCT) can provide reliable evidence on the effectiveness of interventions, they also have inherent limitations including high cost and long execution time. In addition, rcts usually are conducted on selected populations and in specialized environments with limited follow up time. Therefore, they could have limitations in generalizability to real-world clinical practice. Clinical trial simulation is becoming an effective approach to assess feasibility, investigate assumptions, and refine study protocols before conducting the actual trials. Increased availability and granularity of real-world data (RWD) such as electronic health record (EHR) and medical claims data along with advances in data science offer untapped opportunities to leverage RWD for trial simulation studies to generate real world evidence (RWE). Nevertheless, there are methodological barriers and informatics challenges in supporting RWD-based trial simulation studies, especially for ad: (1) clinical trials need to be represented using a formal and standard approach (i.e., ontologies) to capture the entire scope of a trial, especially eligibility criteria and outcome measures (i.e., both effectiveness and safety); (2) such formal and standard representation needs to be made interoperable with RWD standards (e.g., common data models) to identify study cohorts and relevant, important patient characteristics (i.e., via computable phenotypes and natural language processing [NLP] methods as rich ad-related information such as cognitive scores often exist in unstructured clinical notes); and (3) comprehensive and reusable pipelines need to be implemented that can seamlessly align with existing large-scale RWD for generating high-quality analytic-ready datasets for ad clinical trial simulation studies. To address these barriers, we propose create and pilot test the acts (alzheimer's disease clinical trial simulation) system, leveraging three large collections of RWD (~20 million patients from the oneflorida network, UT physician clinical data research warehouse, and the optum's clinformatics data). Specifically, we propose to develop novel informatics approaches to represent the entirety of ad trials while considering the connection of RWD (aim 1), to use both structured and unstructured RWD to develop robust phenotyping algorithms that will render previously incomputable ad study traits computable (aim 2), and to develop the acts web application, which will provide an integrated environment for ad researchers to construct virtual ad trials using an interactive web interface and obtain analytic-ready datasets for trial simulation studies (aim 3).
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $993,414 | |
| Amendment | $973,545 | |
| Amendment | $973,545 | |
| Amendment | $973,545 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $939,381 | |
| Amendment | -$939,381 | |
| Amendment | -$939,381 | |
| Amendment | $939,381 | |
| Amendment | -$939,381 | |
| Amendment | $939,381 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,021,664 | |
| Amendment | $1,021,664 | |
| Amendment | $1,021,664 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,155,311 | |
| Amendment | $1,155,311 | |
| Amendment | $1,155,311 | |
| Amendment | $1,155,311 | |
| Amendment | -$1,155,311 | |
| Amendment | -$1,155,311 | |
| Amendment | -$1,155,311 | |
| Amendment | -$1,155,311 | |
| Amendment | -$1,155,311 | |
| Amendment | $1,155,311 | |
| Amendment | $1,155,311 | |
| Original award | $1,155,311 |
Show all 34
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Texas Health Science Center At Houston | $312,000 | |
| Regenstrief Institute Inc. | $96,389 | |
| Trustees Of Indiana University | $206,403 | |
| Trustees Of Indiana University | $47,437 | |
| University Of Texas Health Science Center At Houston | $505,440 |
Quick answers
Who received award R01AG084236?
R01AG084236 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute on Aging (National Institutes of Health) on September 1, 2023.
How much is award R01AG084236 worth?
$9,289,663 has been obligated on R01AG084236.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award